Design of Phase III study testing buntanetap efficacy in early Alzheimer's patients based on the insights from previous studies

Abstract

Background: By inhibiting the translation of neurotoxic aggregating proteins ‐ amyloid precursor protein, tau, alpha‐synuclein, and TDP43 etc., buntanetap restores axonal transport, lowers inflammation, and protects nerve cells from dying.

The paper